These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 9686787)

  • 1. Dose standardization of botulinum toxin.
    Krack P; Deuschl G; Benecke R; Ceballos-Baumann AO; Marion MH; Oertel WH; Poewe W
    Mov Disord; 1998 Jul; 13(4):749-51. PubMed ID: 9686787
    [No Abstract]   [Full Text] [Related]  

  • 2. Botulinum toxin A-when is a unit not a unit?
    Harper L
    J Urol; 2009 Jan; 181(1):414; discussion 414-5. PubMed ID: 19019386
    [No Abstract]   [Full Text] [Related]  

  • 3. Dose equivalence of two commercial preparations of botulinum neurotoxin type A: time for a reassessment?
    Wohlfarth K; Sycha T; Ranoux D; Naver H; Caird D
    Curr Med Res Opin; 2009 Jul; 25(7):1573-84. PubMed ID: 19463043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Botulinum toxin type A (Botox) in the treatment of migraine and other headaches.
    Troost BT
    Expert Rev Neurother; 2004 Jan; 4(1):27-31. PubMed ID: 15853612
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of purification on the bioavailability of botulinum neurotoxin type A.
    Cheng LW; Onisko B; Johnson EA; Reader JR; Griffey SM; Larson AE; Tepp WH; Stanker LH; Brandon DL; Carter JM
    Toxicology; 2008 Jul; 249(2-3):123-9. PubMed ID: 18538461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of the therapeutic indexes of different molecular forms of botulinum toxin type A.
    Yoneda S; Shimazawa M; Kato M; Nonoyama A; Torii Y; Nishino H; Sugimoto N; Kozaki S; Hara H
    Eur J Pharmacol; 2005 Jan; 508(1-3):223-9. PubMed ID: 15680275
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin for cervical dystonia.
    Med Lett Drugs Ther; 2001 Jul; 43(1109):63-4. PubMed ID: 11468603
    [No Abstract]   [Full Text] [Related]  

  • 8. Dose standardization of botulinum toxin.
    Van den Bergh PY; Lison DF
    Adv Neurol; 1998; 78():231-5. PubMed ID: 9750920
    [No Abstract]   [Full Text] [Related]  

  • 9. What is the optimum dose of type a botulinum toxin for treating neurogenic bladder overactivity?
    Shah J; Patki P; Patil K; Wood S
    BJU Int; 2006 Aug; 98(2):466-7. PubMed ID: 16879701
    [No Abstract]   [Full Text] [Related]  

  • 10. Intraprostatic botulinum toxin a injection inhibits cyclooxygenase-2 expression and suppresses prostatic pain on capsaicin induced prostatitis model in rat.
    Chuang YC; Yoshimura N; Huang CC; Wu M; Chiang PH; Chancellor MB
    J Urol; 2008 Aug; 180(2):742-8. PubMed ID: 18554636
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Botulinum toxin (Botox Cosmetic) for frown lines.
    Med Lett Drugs Ther; 2002 May; 44(1131):47-8. PubMed ID: 12045752
    [No Abstract]   [Full Text] [Related]  

  • 12. Pharmacokinetic properties of different formulations of botulinum neurotoxin type A.
    Wohlfarth K; Kampe K; Bigalke H
    Mov Disord; 2004 Mar; 19 Suppl 8():S65-7. PubMed ID: 15027057
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Influence of age and gender on dose and effectiveness of botulinum toxin for laryngeal dystonia.
    Vasconcelos S; Birkent H; Sardesai MG; Merati AL; Hillel AD
    Laryngoscope; 2009 Oct; 119(10):2004-7. PubMed ID: 19572275
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study.
    Dykstra DD; Presthus J
    J Reprod Med; 2006 Jun; 51(6):467-70. PubMed ID: 16846084
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of volume and concentration on the diffusion of botulinum exotoxin A.
    Hsu TS; Dover JS; Arndt KA
    Arch Dermatol; 2004 Nov; 140(11):1351-4. PubMed ID: 15545544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of hyperfunctional facial lines with botulinum toxin].
    Böni R; Kargl A; Kreyden OP; Burg G
    Praxis (Bern 1994); 2001 Aug; 90(34):1408-12. PubMed ID: 11552321
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Do different formulations of botulinum toxin type A really have different migration characteristics?
    Karsai S; Raulin C
    J Cosmet Dermatol; 2008 Sep; 7(3):230. PubMed ID: 18789061
    [No Abstract]   [Full Text] [Related]  

  • 18. [Management of spastic cerebral palsy with botulinum-A toxin: relationship between dosage and efficacy].
    Wang YJ; Yan GY; Gao BQ
    Zhongguo Dang Dai Er Ke Za Zhi; 2007 Jun; 9(3):247-8. PubMed ID: 17582266
    [No Abstract]   [Full Text] [Related]  

  • 19. [Safety and tolerance of single-dose botulinum toxin Type A treatment in 204 patients with spasticity and localized associated symptoms. Austrian and German botulinum toxin A spasticity study group].
    Wissel J; Müller J; Heinen F; Mall V; Sojer M; Ebersbach G; Poewe W
    Wien Klin Wochenschr; 1999 Oct; 111(20):837-42. PubMed ID: 10586488
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ultrasound-guided, intraglandular injection of botulinum toxin A in children suffering from excessive salivation.
    Gerlinger I; Szalai G; Hollódy K; Németh A
    J Laryngol Otol; 2007 Oct; 121(10):947-51. PubMed ID: 17391573
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.